<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30189722</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>07</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2005-9256</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>Cancer research and treatment : official journal of Korean Cancer Association</Title>                <ISOAbbreviation>Cancer Res Treat</ISOAbbreviation>            </Journal>            <ArticleTitle>Discordance of the PAM50 Intrinsic Subtypes Compared with IHC-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.4143/crt.2018.342</ELocationID>            <Abstract>                <AbstractText Label="Purpose" NlmCategory="UNASSIGNED">We aimed to analyze the discordance between immunohistochemistry (IHC)-based surrogate subtyping and PAM50 intrinsic subtypes and to assess overall survival (OS) according to discordance.</AbstractText>                <AbstractText Label="Materials and Methods" NlmCategory="UNASSIGNED">A total of 607 patients were analyzed. Hormone receptor (HR) expression was evaluated by IHC, and human epidermal growth factor receptor 2 (HER2) expression was analyzed by IHC and/or fluorescence in situ hybridization. PAM50 intrinsic subtypes were determined according to 50 cancer genes using the NanoString nCounter Analysis System. We matched concordant tumor as luminal A and HR+/HER2-, luminal B and HR+/HER2+, HR-/HER2+ and Her2-enriched, and triple-negative breast cancer and normal- or basal-like. We used Ion Ampliseq Cancer Panel v2 was used to identify the genomic alteration related with discordance. The Kaplan-Meier method was used to estimate OS.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">In total, 233 patients (38.4%) were discordant between IHC-based subtype and PAM50 intrinsic subtype. Using targeted sequencing, we detected somatic mutation-related discordant breast cancer including the VHL gene in the HR+/HER2- group (31% in concordant group, 0% in discordant group, p=0.03) and the IDH and RET genes (7% vs. 12%, p=0.02, 0% vs. 25%, p=0.02, respectively) in the TNBC group. Among the luminal A/B patients with a discordant result had significantly worse OS (median OS, 73.6 months vs. not reached, P&lt;0.001), and among the patients with HR positivity, the basal-like group as determined by PAM50 showed significantly inferior OS compared to other intrinsic subtypes (5-year OS rate, 92.2% vs. 75.6%, P=0.01).</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">A substantial portion of patients showed discrepancy between IHC subtype and PAM50 intrinsic subtype in our study. The survival analysis demonstrated that current IHC-based classification could mislead the treatment and result in poor outcome. Current guidelines for IHC might be updated accordingly.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Hee Kyung</ForeName>                    <Initials>HK</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Park</LastName>                    <ForeName>Kyung Hee</ForeName>                    <Initials>KH</Initials>                    <AffiliationInfo>                        <Affiliation>Samsung Genome Institute, Samsung Medical Center, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Youjin</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Park</LastName>                    <ForeName>Song Ee</ForeName>                    <Initials>SE</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>Han Sang</ForeName>                    <Initials>HS</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lim</LastName>                    <ForeName>Sung Won</ForeName>                    <Initials>SW</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cho</LastName>                    <ForeName>Jang Ho</ForeName>                    <Initials>JH</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Ji-Yeon</ForeName>                    <Initials>JY</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>Jeong Eon</ForeName>                    <Initials>JE</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ahn</LastName>                    <ForeName>Jin Seok</ForeName>                    <Initials>JS</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Im</LastName>                    <ForeName>Young-Hyuck</ForeName>                    <Initials>YH</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yu</LastName>                    <ForeName>Jong Han</ForeName>                    <Initials>JH</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Park</LastName>                    <ForeName>Yeon Hee</ForeName>                    <Initials>YH</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>05</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Korea (South)</Country>            <MedlineTA>Cancer Res Treat</MedlineTA>            <NlmUniqueID>101155137</NlmUniqueID>            <ISSNLinking>1598-2998</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">Immunohistochemistry</Keyword>            <Keyword MajorTopicYN="N">PAM50</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>8</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30189722</ArticleId>            <ArticleId IdType="pii">crt.2018.342</ArticleId>            <ArticleId IdType="doi">10.4143/crt.2018.342</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>